NRX Pharmaceuticals, Inc. — Director's Dealing 2017

Dec 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Big Rock Partners Acquisition Corp. (BRPAU)
CIK: 0001719406
Period of Report: 2017-11-29

Reporting Person: ACKERMAN RICHARD (N/A)
Reporting Person: Big Rock Partners Sponsor, LLC (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-29	Common Stock	P	22500	$10.00	Acquired	272500	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-29	Right to receive common stock	$	P	22500	Acquired		Common Stock (2250)	Indirect
2017-11-29	Warrant	$11.50	P	11250	Acquired		Common Stock (11250)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1725000	Indirect

Footnotes

F1: Represents securities underlying units of the issuer. Each unit consists of one share of common stock, one right to receive one-tenth of one share of common stock upon the consummation of the issuer's initial business combination and one-half of one warrant, each whole warrant entitling the holder to purchase one share of common stock.

F2: Represents securities purchased upon the exercise of the underwriters' over-allotment option in connection with the issuer's initial public offering.

F3: Mr. Ackerman is the issuer's President, Chairman and Chief Executive Officer and the managing member of Big Rock Partners Sponsor, LLC (the "Sponsor") and has the sole voting and dispositive power of the securities held by the Sponsor. Accordingly. Mr. Ackerman may be deemed to have beneficial ownership of such shares.

F4: Each right entitles the holder to receive one-tenth (1/10) of one share of common stock upon consummation of the issuer's initial business combination.

F5: If the issuer fails to consummate an initial business combination within 12 months (or up to 18 months from the closing of the issuer's initial public offering, if the issuer extends the period of time to consummate a business combination as described in its amended and restated certificate of incorporation), the issuer will be dissolved and the rights will expire worthless.

F6: Each whole warrant will become exercisable on the later of the completion of the issuer's initial business combination and 12 months from the closing of the issuer's initial public offering.

F7: Each warrant will expire on the fifth anniversary of the completion of the issuer's initial business combination, or earlier upon redemption or liquidation.